Jazz to Highlight Narcolepsy and IH Research at AAN 2024
The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
Tag: Jazz Pharmaceuticals
All
Latest
All
Latest
Jazz Highlights Continued Need for Low-Sodium Treatment Option for Narcolepsy and IH
Jazz Pharmaceuticals announced new data highlighting the importance of low-sodium treatment options to help manage cardiovascular risk in patients with narcolepsy and idiopathic hypersomnia.
All
Latest
Differential Diagnosis of Idiopathic Hypersomnia
How do you differentiate idiopathic hypersomnia from hypersomnias of a specific cause, such as narcolepsy type 1 and type 2, insufficient sleep syndrome, or hypersomnia due to a neurodegenerative disease?
Xyrem Generic for Narcolepsy Launches in US
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy.
Read More
Physician Discovers Surprising Possible Side Effect of Xywav in Narcolepsy Patient
A patient with type 2 narcolepsy reports an experience to her sleep physician that was not seen in any of the clinical trials.
Read More
Jazz to Present Seven Abstracts on Idiopathic Hypersomnia and Narcolepsy
Jazz Pharmaceuticals is presenting seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy.
Read More
Jazz Reports Continued Adoption of Xywav for Narcolepsy and IH
Jazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Read More
New Initiative to Educate Sleep Disorder Community on Cardiovascular Risks
With support from Jazz Pharmaceuticals, the American Heart Association will develop education for patients and healthcare providers on the impact of sleep disorders on heart and brain health.
Read More
Axsome Offers Updates on Sunosi and AXS-12
Axsome Therapeutics discusses what’s next for Sunosi, used to reduce excessive daytime sleepiness in adults with narcolepsy or sleep apnea, and AXS-12, a narcolepsy drug candidate in clinical trials.
Read More
Tris Pharma Is Working on a Low Sodium, Once-Nightly Oxybate Formulation for Narcolepsy
Tris has developed an oxybate formulation intended for the treatment of cataplexy or excessive daytime sleepiness in people with narcolepsy.
Read More
Axsome Completes US Acquisition of Sunosi
‘The Sunosi acquisition marks the transformation of Axsome into a commercial neuroscience company and reflects our commitment to the millions of people living with serious neurologic and psychiatric conditions.’
Read More
Jazz Pharmaceuticals Gets Development Rights to Orexin-2 Receptor Agonist with Treatment Potential for Narcolepsy, IH, and More
Jazz Pharmaceuticals has acquired development and commercialization rights in the United States for Sumitomo’s investigational DSP-0187.
Read More
Axsome Therapeutics to Acquire Sunosi from Jazz Pharmaceuticals
The acquisition of Sunosi adds a high-potential commercial asset to Axsome’s late-stage neuroscience portfolio.
Read More
Jazz Updates Xyrem, Xywav Prescription Forms
On February 9, Jazz Pharmaceuticals plc made changes to its XYWAV and XYREM prescription forms to decrease prescriber confusion.
Read More
Xywav Eases Idiopathic Hypersomnia Symptoms, New Data Shows
New clinical trial data shows that the medication Xywav significantly reduced the long sleep duration and excessive daytime sleepiness that are typical hallmarks of the sleep disorder idiopathic hypersomnia.
Read More
FDA Grants Jazz Pharmaceuticals New Exclusivity Rights for Hypersomnia Medication
Jazz announced on Monday that the U.S. Food and Drug Administration granted them Orphan Drug Exclusivity for the medication Xywav for the treatment of idiopathic hypersomnia.
Read MoreNSAIDS May Limit Passage of Narcolepsy Medication Gamma Hydroxybutyric Acid to the Brain
Previous studies completed by the UB researchers found that the NSAIDs ibuprofen and ketoprofen also affected the movement of GHB in the body.
Read More
AASM Releases Clinical Practice Guideline for Hypersomnia Treatment
It provides recommendations to guide clinicians in choosing a prescription medication to treat disorders such as narcolepsy, idiopathic hypersomnia, and Kleine-Levin Syndrome.
Read More